Neuland Labs Reports First Quarter Fiscal Year 2013 Financi... (sed profitability of our mature products...)

Neuland Labs Reports First Quarter Fiscal Year 2013 Financial Results

Date:8/10/2012

sed profitability of our mature products and a significant upsurge in revenues from our contract manufacturing business," noted Sucheth R. Davuluri, Chief Executive Officer of Neuland Labs. "In addition, during the quarter we were honored when D.R. Rao, our founder and Chairman, was featured in a best-selling new book on India's new age entrepreneurs."

Neuland also reported that it is in the process of re-organizing its businesses in order to infuse more capital in a manner that will increase the focus on new product development, reduce costs and further de-leverage the balance sheet, thereby setting the stage for creating additional value for shareholders going forward. The company intends to provide additional information on these developments in the coming months.

For a complete set of Neuland's FY 2013 and FY 2012 financial data, visit http://neulandlabs.com/about/financials.html.Neuland Laboratories is listed on India's National Stock Exchange under the symbol NEULANDLAB and on the Bombay Stock Exchange under code 524558 and the symbol Neuland.EO.* = Indian rupees

About Neuland LabsFor over 25 years Neuland Labs has been at the forefront of supporting drug development through its consulting services and its cGMP contract and API manufacturing. The company is committed to research, supporting a state-of-the-art R&D operation. Neuland Labs scientists have developed more than 300 processes from bench scale to commercial production and filed more than 400 drug master files worldwide. Its manufacturing facilities are inspected and approved by the FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the FDA, TGA, EDQM, German Health Authority, ISO 14001, ISO 27001 and
'/>"/>

SOURCE Neuland Laboratories Ltd.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Neuland Labs Reports Financial Results For Fiscal Year 2012
2. Patient Safety Technologies Reports Second Quarter 2012 Results
3. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
4. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
5. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
6. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. CareFusion Reports Fourth Quarter and Fiscal 2012 Results
9. American Pacific Reports Fiscal 2012 Third Quarter Results; Full Year Guidance Improves
10. Winner Medical Reports Third Quarter Fiscal 2012 Results
11. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results

Post Your Comments:

(Date:6/19/2013)... BURLINGTON, Mass. , June 19, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... the majority of surveyed U.S. and European rheumatologists ... of the attributes that most influences their prescribing ... U.S. and European rheumatologists, respectively, rank the percentage ...

(Date:6/19/2013)... , June 19, 2013 BD Biosciences, a segment ... ), a leading global medical technology company, today announced the ... the latest in its line of high-performance research flow cytometers. ... high-performance multicolor analysis with the most compact footprint in its ... and a height of 30" (76.2 cm). Recognizing that space ...

(Date:6/19/2013)... PRINCETON, N.J. , June 19, 2013 ... Belrose Pharma, a new specialty pharmaceutical company ... generation of innovative injectable and sustained release ... high unmet medical needs, today announced the ... (Customized Linker Technology®) platform and associated product ...

Breaking Medicine Technology:U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2 New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2 Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2 Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3 Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4

[0] U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis [0] New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research [0] Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies

... YORK, Oct. 24, 2011 Reportlinker.com ... report is available in its catalogue: ... to 2017 - Glaucoma and Cataract ... Ophthalmic Surgery to Drive the Ophthalmic ...

... 2011 Phreesia, the patient check-in company, is committed ... practices nationwide with its electronic self-service check-in solution. One ... for practices is by automating the eligibility and benefits ... accurate billing by confirming coverage prior to the exam. ...

Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market Phreesia Continues to Enhance its Market-Leading Eligibility and Benefits Verification Process for Medical Practices

(Date:6/19/2013)... Quapaw, OK (PRWEB) June 19, 2013 ... of Companies, including RWI Benefits, LLC, Native Care ... The National Association of Health Underwriters’ (NAHU) new ... Affordable Care Act (PPACA). This continuing education course ... states, and Roberson will receive eleven education credits ...

(Date:6/19/2013)... According to a June 17, 2013 Allure ... is not uncommon for a person to suffer from a ... is likely to forget to reapply sunscreen properly and end ... and itchy. When this occurs, it is essential to act ... people do not realize that milk contains proteins, fats, and ...

(Date:6/19/2013)... In a major international study led by researchers at ... targeted therapy ibrutinib continues to show remarkable promise for ... (MCL). , The most recent interim findings of the ... New England Journal of Medicine . Previous interim ... American Society of Hematology Annual Meeting and Exposition. ...

(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...

(Date:6/19/2013)... reveals significant disparities between minority and white clients ... programs. Moreover, these disparities vary widely from state ... for most states there,s something amiss," says Stephan ... "There are strong racial and ethnic disparities for ... treatment programs successfully, and those disparities are something ...

Breaking Medicine News(10 mins):Health News:RWI Benefits, LLC Becomes PPACA Certified 2 Health News:Skin Care – How to treat Sunburn 2 Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2 Health News:Neurosurgery publishes findings of 3 important studies in June issue 2 Health News:Neurosurgery publishes findings of 3 important studies in June issue 3 Health News:States vary widely on success rates for minorities in drug treatment programs 2 Health News:States vary widely on success rates for minorities in drug treatment programs 3

[0] RWI Benefits, LLC Becomes PPACA Certified [0] Skin Care – How to treat Sunburn [0] Ibrutinib continues strong showing against mantle cell lymphoma [0] Neurosurgery publishes findings of 3 important studies in June issue [0] States vary widely on success rates for minorities in drug treatment programs

... Dec. 1 Acuo Technologies(R), developers,of high-performance software ... services, today announced the contracting with Rush,University ... new vendor neutral archiving,solution which becomes the basis ... archiving solution is based on the Acuo Technologies ...

... In recognition of World AIDS Day, Charlotte Bobcats, Emeka Okafor, will ... One Million African Lives Initiative (OMALI), a program of the Safe ... is to save one million lives in Africa by 2011 by ... , , OMALI will be ...

... TOMS Shoes, the philanthropic,footwear company, has launched a ... and Give More this holiday season. For 30,days, from ... to help give 30,000 pairs of shoes to children ... preventable by wearing shoes. By,purchasing a pair of shoes ...

... , , ANN ARBOR, ... pajamas or a video game are all quick and easy gifts to ... not give something more healthy and beneficial to a loved one? Why ... Staying healthy around the holidays can be challenging, and this ...

... Dec. 1 TorreyPines Therapeutics, Inc.,(Nasdaq: ... administration of NGX426, an,AMPA/kainate-type glutamate receptor antagonist, ... hyperalgesia (abnormally increased,pain state) and allodynia (pain ... compared to placebo following intradermal injections of ...

... Horvath, D.V.M., as Vice President of Preclinical Sciences and ... , CAMBRIDGE, Mass., Dec. ... Mass.-based executive team with the appointment of Jeffrey T. ... announced the additions of Christopher Horvath, D.V.M., as vice ...

Cached Medicine News:Health News:Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center 2 Health News:Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center 3 Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2 Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2 Health News:Giving the Gift of Health This Holiday Season 2 Health News:Giving the Gift of Health This Holiday Season 3 Health News:Giving the Gift of Health This Holiday Season 4 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5 Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 2 Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 3

Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days!Giving the Gift of Health This Holiday Season TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

... to provide excellent protection and ease of ... being closer to an adhesive in molecular ... CoEase to maintain viscosity at high shear ... worlds for superb performance during capsulorhexis, phaco, ...

... viscosurgical device is a cohesive ... high molecular weight, high pseudoplasticity, ... provides excellent space maintenance, facilitates ... removed. It is available in ...

... VISUCAM DigitalCameras permit fundus imaging and ... operation without any need for eyepieces ... findings. Image recording and display is ... utilizes the ophthalmoscope principle of modern ...

... The ARIS A utomated R ... revolutionary, patented technology which provides rapid and automated ... allows eye care professionals to screen and ... in less time and at ...

Medicine Products:

CoEase ProVisc VISUCAM Digital Camera ARIS Automated Retinal Imaging System